Generics Bulletin Managing Editor Dave Wallace has nearly 10 years experience of reporting on the global generic, biosimilar, value-added and OTC medicines industries. Bringing his background and education in law to bear on industry litigation - as well as national legislative and regulatory affairs - he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and judges the annual Global Generics & Biosimilars Awards. A French speaker, Dave enjoys music - with a love of the piano - and visual arts.
Latest From David Wallace
The UK’s Competition and Markets Authority has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.
At a Medicines for Europe webinar on learning lessons from the COVID-19 pandemic, a clear consensus emerged that a continued co-ordination between industry, regulators and the European Commission was key to both effectively address the current crisis and ensure a greater level of preparedness for similar challenges in future.
The UK’s CMA has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.
Sanofi has received formal approval from the European Commission for its insulin aspart biosimilar.
Mylan’s Hulio has become the sixth biosimilar version of Humira to be approved by the US FDA. However, all of these adalimumab biosimilars face a wait until 2023 before they can enter the market.
The Global Generics & Biosimilars Awards 2020 will take place on 3 November as a digital event, with a newly-extended entry deadline date of 14 August.